Fluticasone Propionate Powder, Metered
NDC Package 66993-791-97
Package Information
Fluticasone Propionate powders is fluticasone Propionate DISKUS is indicated for the maintenance treatment of asthma as prophylactic therapy in patients aged 4 years and older.Important Limitation of UseFluticasone Propionate DISKUS is NOT indicated for the relief of acute bronchospasm. This formulation utilizes a powder, metered delivery system. Marketed by Prasco Laboratories, this product is identified by NDC 66993-791 and is authorized under FDA application NDA020833.
Identification & Billing
- RxCUI: 896018 - fluticasone propionate 50 MCG/INHAL Dry Powder Inhaler, 60 Blisters
- RxCUI: 896018 - 60 ACTUAT fluticasone propionate 0.05 MG/ACTUAT Dry Powder Inhaler
- RxCUI: 896018 - fluticasone propionate 0.05 MG/ACTUAT Dry Powder Inhaler, 60 ACTUAT
- RxCUI: 896021 - fluticasone propionate 100 MCG/INHAL Dry Powder Inhaler, 60 Blisters
- RxCUI: 896021 - 60 ACTUAT fluticasone propionate 0.1 MG/ACTUAT Dry Powder Inhaler
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 66993 - Prasco Laboratories
- 66993-791 - Fluticasone Propionate
- 66993-791-97 - 1 INHALER in 1 CARTON / 60 POWDER, METERED in 1 INHALER
- 66993-791 - Fluticasone Propionate
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 66993-791-97 identifies a specific commercial package of 1 inhaler in 1 carton / 60 powder, metered in 1 inhaler of Fluticasone Propionate Diskus, a human prescription drug labeled by Prasco Laboratories. This powder, metered is formulated for respiratory (inhalation) use and contains fluticasone propionate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Prasco Laboratories on October 30, 2023. The current certification is valid through December 31, 2027.
How is this Prasco Laboratories product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 66993079197. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.